- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
- 10-K Annual report
- 23.1 Consent of Bdo USA, LLP, Independent Registered Public Accounting Firm
- 31.1 Certification by CEO Pursuant to Section 302
- 31.2 Certification by CFO Pursuant to Section 302
- 32.1 Certification by CEO Pursuant to Section 906
- 32.2 Certification by CFO Pursuant to Section 906
- Download Excel data file
- View Excel data file
Adamis Pharmaceuticals Corporation 10-K
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Adamis Pharmaceuticals Corporation
11682 El Camino Real, Suite #300
San Diego, CA 92130
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-159229, 333-169106, 333-175383, 333-194635, 333-201742, 333-211773, 333-218945, 333-226230, and 333-229379), and Form S-3 (Nos. 333-196976, 333-199454, 333-200447, 333-209401, 333-212880, 333-217400, 333-217408, 333-226100, 333-267365 and 333-249331) of Adamis Pharmaceuticals Corporation (the “Company”) of our report dated March 16, 2023, relating to the consolidated financial statements, which appear in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
San Diego, CA 92130
March 16, 2023